We are live on ! Find out more
SPPI

Spectrum Pharmaceuticals Inc

Delisted

SPPI was delisted on the 31st of July, 2023.

176 hedge funds and large institutions have $757M invested in Spectrum Pharmaceuticals Inc in 2018 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 66 increasing their positions, 54 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 54

7% less funds holding

Funds holding: 190176 (-14)

41% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 32

46% less call options, than puts

Call options by funds: $684K | Put options by funds: $1.28M

50% less capital invested

Capital invested by funds: $1.51B → $757M (-$748M)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
176
Holders Change
-14
Holders Change %
-7.37%
% of All Funds
3.92%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
19
Increased
66
Reduced
54
Closed
32
Calls
$684K
Puts
$1.28M
Net Calls
-$594K
Net Calls Change
-$3.98M
Name Holding Trade Value Shares
Change
Change in
Stake
TA
26
Teachers Advisors
New York
$5.14M +$602K +47,225 +9%
Charles Schwab
27
Charles Schwab
California
$4.87M -$542K -42,544 -7%
Point72 Asset Management
28
Point72 Asset Management
Connecticut
$4.72M +$5.37M +421,900 +360%
Citigroup
29
Citigroup
New York
$4.33M +$5.73M +449,504 +979%
SIG
30
Sargent Investment Group
Maryland
$3.92M +$5.71M +447,995 New
PAM
31
Panagora Asset Management
Massachusetts
$3.79M -$3.23M -253,289 -37%
Deutsche Bank
32
Deutsche Bank
Germany
$3.57M -$3.92M -307,514 -43%
TCIM
33
TIAA CREF Investment Management
New York
$3.06M -$734K -57,622 -14%
Balyasny Asset Management
34
Balyasny Asset Management
Illinois
$2.71M +$3.94M +309,497 New
ACM
35
Ashford Capital Management
Delaware
$2.56M -$3.13M -245,515 -46%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$2.54M +$719K +56,471 +24%
JGC
37
J. Goldman & Co
New York
$2.34M -$1.8M -141,625 -35%
Legal & General Group
38
Legal & General Group
United Kingdom
$2.25M +$212K +16,608 +7%
JP Morgan Chase
39
JP Morgan Chase
New York
$2.12M +$2.74M +215,290 +815%
UBS Group
40
UBS Group
Switzerland
$1.81M -$1.26M -98,562 -32%
Bank of America
41
Bank of America
North Carolina
$1.62M +$1.28M +100,649 +118%
Citadel Advisors
42
Citadel Advisors
Florida
$1.58M -$17.7M -1,390,037 -88%
Fisher Asset Management
43
Fisher Asset Management
Washington
$1.58M
Millennium Management
44
Millennium Management
New York
$1.52M +$1.54M +120,541 +225%
Swiss National Bank
45
Swiss National Bank
Switzerland
$1.48M +$66.2K +5,200 +3%
Prudential Financial
46
Prudential Financial
New Jersey
$1.45M -$120K -9,405 -5%
AllianceBernstein
47
AllianceBernstein
Tennessee
$1.43M -$1.08M -85,000 -34%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$1.38M +$46.7K +3,668 +2%
ASRS
49
Arizona State Retirement System
Arizona
$1.37M +$166K +13,015 +9%
GC
50
Guggenheim Capital
Illinois
$1.36M +$283K +22,191 +17%

SPPI Hedge Fund Activity: Q4 2018 in Review

176 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Spectrum Pharmaceuticals Inc (SPPI) for Q4 2018, worth a combined $757M — down 50% from $1.51B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of SPPI and 19 opened new positions — a net loss of 13 holders — while 54 trimmed existing stakes and 66 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $19.1M. The largest seller was Consonance Capital Management, cutting an estimated $36.4M.

  • 176 institutional investors held Spectrum Pharmaceuticals Inc (SPPI) as of Q4 2018, down from 190 in Q3 2018.
  • Funds reported $757M of Spectrum Pharmaceuticals Inc stock for Q4 2018, down 50% quarter-over-quarter.
  • 19 funds opened new Spectrum Pharmaceuticals Inc positions in Q4 2018 and 32 closed out, a net change of -13 holders.
  • The largest Spectrum Pharmaceuticals Inc buyer in Q4 2018 was Armistice Capital, an estimated $19.1M added.
  • The largest Spectrum Pharmaceuticals Inc seller in Q4 2018 was Consonance Capital Management, an estimated $36.4M sold.

Based on aggregated 13F filings for Q4 2018.